Medscape reports the US Food and Drug Administration (FDA) has approved the first nasally administered glucagon product (Baqsimi, Eli Lilly and Co) for the treatment of severe hypoglycemia for patients aged 4 years or older who have diabetes.

The nasal powder is the first licensed glucagon product that is not delivered by injection and that does not require a multistep mixing process.